1. Home
  2. NFE vs NGNE Comparison

NFE vs NGNE Comparison

Compare NFE & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Fortress Energy Inc.

NFE

New Fortress Energy Inc.

HOLD

Current Price

$0.64

Market Cap

324.4M

Sector

Utilities

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$27.21

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NFE
NGNE
Founded
2014
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.4M
327.8M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
NFE
NGNE
Price
$0.64
$27.21
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$7.63
$63.57
AVG Volume (30 Days)
7.9M
148.2K
Earning Date
04-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.93
EPS
N/A
N/A
Revenue
$1,504,037,000.00
N/A
Revenue This Year
$110.34
N/A
Revenue Next Year
$3.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$11.78
52 Week High
$6.37
$37.27

Technical Indicators

Market Signals
Indicator
NFE
NGNE
Relative Strength Index (RSI) 39.91 65.32
Support Level $0.56 $19.40
Resistance Level $0.77 $29.05
Average True Range (ATR) 0.07 1.88
MACD 0.02 0.45
Stochastic Oscillator 21.80 81.15

Price Performance

Historical Comparison
NFE
NGNE

About NFE New Fortress Energy Inc.

New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: